Developing a framework regarding a complex risk-based methodology in the evaluation of hazards associated with medicinal products sourced via the internet

Róbert György Vida\textsuperscript{a,}*, Sára Merczel\textsuperscript{b}, Eszter Ján\textsuperscript{a}, András Fittler\textsuperscript{a}

\textsuperscript{a} University of Pécs, Faculty of Pharmacy, Department of Pharmaceutics and Central Clinical Pharmacy, Honvéd Street 3, 7624 Pécs, Hungary
\textsuperscript{b} Department of Pharmacy, Somogy County Kaposi Mór Teaching Hospital, Tallián Gyula Street 20-32, 7400 Kaposvár, Hungary

**A R T I C L E   I N F O**

Article history:
Received 31 July 2020
Accepted 31 October 2020
Available online 6 November 2020

Keywords:
Internet pharmacy
Risk assessment
Eye drops
Counterfeit medicine
Online medicines
Test purchase

**A B S T R A C T**

Today, the increasing number of illicit internet pharmacies is a global phenomenon, however, the size of the online pharmaceutical market is still relatively unknown and the dubious quality of products is questionable and warrants investigation. Descriptive data from this black market channel are derived from studies analyzing the online availability of different medications procured over the internet and their methodology is quite heterogeneous. Our aim was to develop a comprehensive and specific risk assessment for selecting high patient safety risk medications from the online pharmaceutical market. A rapid tool was developed based upon the two quality and safety standard resolutions in pharmaceutical practice, published by the European Directorate for the Quality of Medicines, and was illustrated on eye drops. We developed five dimensions in support of the risk assessment including intrinsic, extrinsic and potential risks of counterfeiting. The five criteria were integrated in a comprehensively weighted risk-scoring format. The probability of procuring the product from the internet was also assessed based on the number of relevant links within the first twenty search engine results and the cost of the products. With the application of the tool a dorzolamide & timolol combination eye drop represented the highest overall patient safety risk score. In consideration of our literature review of the past 20 years, there is no current, standardized methodology to effectively identify pharmaceutical products associated with high patient safety risks. Notably, the fully comprehensive analysis of the internet pharmaceutical market and the test purchase of all online available medicines is unrealistic. Therefore, we developed a method to aid online surveillance researches and targeted international organizational led joint actions against the uncontrolled sale of falsified and substandard medications (e.g.: Operation Pangea).

© 2020 The Authors. Published by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

1. Introduction

The expanding market of illicit internet pharmacies is a global public health threat with potential negative patient safety consequences in every aspect of our health care system. Although we primarily have indirect fragments of information regarding illegitimate vendors, it is highly likely illegal online pharmacies outnumber legitimate counterparts (Liang and Mackey, 2009; Gabay, 2015). Google searches in reference to the term, “online pharmacy” revealed more than half of the search results were linked to fraudulent sites (Abbasi et al., 2012). According to the survey of the National Association of Boards of Pharmacy (NABP), in 2017, 95.7% of 11,749 online pharmacies were noncompliant with the U.S. legislation and standards (The National Association of Boards of Pharmacy, 2018).

The majority of these “Not Recommended” sites were found to be dispensing prescription-only medicines without a valid prescription (The National Association of Boards of Pharmacy, 2018). In 2016, based on the available industry data (LegitScript), there were 30,000 to 35,000 illicit online pharmacies (Corazza et al., 2014; LegitScript, 2016), and the market was estimated to grow by twenty online vendors daily (LegitScript, 2016).
Also more and more consumers are turning to the digital market to purchase medicine, as it is believed 1–10% of the general population procured at least once a healthcare product using the internet (Orizio et al., 2009, 2011; Fittler et al., 2018a).

Additionally, there are no exceptions, as nearly every therapeutic area is available over the Internet, from “lifestyle drugs” to lifesaving medications (Fittler et al., 2018b; Mackey et al., 2015; Mackey and Nayyar, 2016).

The available public data and literature regarding the internet sales of pharmaceuticals mainly focus on the surface web and simulate the behavior of a potential consumer. Therefore, the data is typically derived from studies analyzing the online availability and quality of different medications or other healthcare products procured using the internet (Orizio et al., 2011; Norbutas, 2018; Vida et al., 2017, 2019).

The authors collected and reviewed publications on test purchases from the online pharmaceutical market in the last 20 years to find out whether these methods included any prior risk assessment to choose the model products for the evaluation of online accessibility or test purchase. These studies provide the highest level of evidence about the illicit online pharmacy market and the associated patient safety risks. We searched the PubMed for relevant literature with ‘internet pharmacy purchase’ and ‘internet pharmacy quality’ key words in 2020. May. Further, review articles in this field from Orizio et al. (2011) and Mackey and Nayyar (2016) were included (Orizio et al., 2011; Mackey and Nayyar, 2016).

We included studies where the visit of the internet pharmacy and the attempt of purchase was carried out, regardless of actual purchase.

Online patient safety evaluation studies (n = 43) were categorized into four main groups, (1) pre-purchase vendor analysis for the estimation of patient safety issues, (2) actual test purchase with product quality analysis, (3) combined vendor, transport and product analysis, and (4) patient safety analysis using patient profiles/cases. In the latter category two studies from 1999 and 2005 used hypothetical patient profiles to evaluate whether there is a proper patient- and medication history checking when purchasing online sildenafil (1999 (Eysenbach, 1999) or hormonal contraceptives (2005, Memmel et al., 2006). In both cases the researchers could purchase the medications easily despite the several contraindications and interacting medications. It was also observed that there were no medical follow up after buying these medications, latter email or telephone contact by the vendors was for marketing purposes. Nine studies assessed only the quality of the purchased products (category 2) with various non-destructive methods (qualitative analysis without physical contact e.g.: near infra-red (NIR) and Raman spectroscopy) and destructive analytical techniques (qualitative and/ on quantitative analysis where the integrity of medications was affected). The main methods were those recommended by the Pharmacopoeias and monographs (e.g.: HPLC for chemical analysis and methods to analyze formulations and dosage form integrity). 41.8% (18) of the studies were pre-purchase studies, as they did not order the actual product, they assessed if the product is available through the internet and what are the main characteristics of the online pharmacies (mainly illegal ones). We have identified a chronological development in the methods used, as assessments after the millennium focused on online prescribing and cyber doctors, price comparisons (mainly US and Canadian prices), shipping destinations, packaging and labeling. From 2005 more and more studies used the NABP VIPPS legitimacy verification (launched in 1999) (NABP) as an element in the assessment of the online vendors. From 2011 the CIPA and PharmacyChecker, while from 2013 the LegitScript was also used as a tool the differentiate between legal, illegal or unregulated internet pharmacies, and from 2014 the EU common logo also appeared in publications. We identified in the studies that the first domain analysis (WHOIS) was published in 2011, while the evaluation of other possible sources like social media (e.g.: Facebook, Twitter, Instagram) and global B2B trading platforms (e.g.: Alibaba) were incorporated first in 2013 by Mackey et al. (2015).

32.5% (14) of the test purchases used a combined method (14). Veronin et al. (2007) and the European Alliance for Access to Safe Medicines EAASM publications (EAASM, 2008) were the first ones to use these methods from 2006. The first comprehensive analyses was made by Gelatti et al. in 2011 (Gelatti et al., 2013), when they ordered fluoxetine pills from several online pharmacies and before the website analysis, they completed a packaging, chemical and microbiological analyses of the ordered product. This and the Authors’ (Vida et al., 2017) analysis incorporated microbiological aspects of the internet market of the pharmaceuticals, however the latter did not carry out actual analysis.

When we look at the regional distribution of the studies, it can be seen that countries with more historical background of the mail order pharmacies were the primary locations, like the USA and Canada (18). The first European publication dates back in 2008 (altogether 11), while from 2009 we can see studies from Japan (5), while the first Australian study was published only in 2019. Regions from developing and transitional countries, and the Middle-East are represented with only one publication from 2018 (United Arab Emirates).

If we look at the search engines used in these studies, the leading role of the Google (17) is not a surprise, the second is Yahoo! (9) and the third most commonly used search engine was Bing (4) in this last twenty-period year.

Out of 31 only 18 test purchases (58.1%) included prior selection method. These included most commonly the following – partly overlapping - four criteria: (1) product with significant sale; (2) commonly used, recommended by guidelines; (3) there is high risk of ADR (e.g.: diazepam, fluoxetine); (4) most popular based on online searches.

Test purchases focused on oral dosage forms (29/25, 80%), only 4 (16%) included multiple dosage forms (e.g.: patch, inhalator) and 1 with just parenteral dosage form (somatropin). The most popular active pharmaceutical ingredients were the erectile dysfunction treatment sildenafil, the cholesterol lowering products simvastatin (5 purchases respectively), atorvastatin (4 purchases) and the antidepressant fluoxetine (3 purchases). Twenty two studies (51.2%) included multiple active pharmaceutical ingredients or products. Not surprisingly, the above list is in line with the global blockbuster drug sales in the year of the studies (Debnath et al., 2010). (The summary of the published literature can be seen in a Supplement 1.)

In 2017, our research group aimed to develop a more comprehensive method regarding the combination and categorization of the aforementioned characteristics associated with internet pharmacies aligned with chemical analysis (Vida et al., 2017). We have been using the perspective of the patient safety risk in our research, however we have not called it risk assessment and have not incorporated into a constructed tool. The selection of the active ingredient was based on the popularity, illegal use and parenteral dosage form, as we thought these characteristics are patient safety risk factors and facilitate the online sell and purchase of somatropin, while the products searched online were based on the national sales. The authors believe it is now timely to develop a patient safety risk assessment method in support of the selection of high-risk model products procured online, and to evaluate the online pharmaceutical market. Also, we believe these patient safety surveillance studies will provide an increased awareness to the potential risks associated with the digital market of pharmaceuticals. Moreover, this method can also be used as a preliminary analysis for the annual Operation Pangea (Mackey and Nayyar, 2018).
Our aim was to develop a complex method to select products associated with a high patient safety risk regarding the online pharmaceutical market. With the inclusion of risk factors originating from the product itself, consumer perspective, and potential of counterfeiting will result in improved surveillance and test procurement studies.

Thus, an original complex risk assessment methodology has been developed based on published literature and professional expertise to provide a recommended tool for research and authority test procurement. This general tool can be used for most medication classes, however adaptation to the specific properties to the given drug group is required. In order to illustrate the real world applicability of the developed risk assessment method, various ophthalmic medications have been evaluated, and the assessment of online availability regarding high-risk products have been completed.

2. Methods

2.1. Research instrument

Patient safety is comprised of several definitions throughout published literature. We define patient safety risk based on the broader perspective of medication errors, since patient safety risk is a risk which may cause or lead to inappropriate medication use and patient harm based on the characteristics of the product itself or the environment (beyond the traditional drug supply chain and control of health care system) while the medication is in the control of the patient or consumer. Based on these definitions, we assumed inappropriate medication use can lead to patient harm by increasing the likelihood of Adverse Drug Events (ADEs) (Hughes, 2008; WHO, 2020; FIP, 2020).

ADE is defined by the WHO as any untoward occurrence which may present itself during treatment associated with a pharmaceutical product which does not necessarily have a causal relationship to treatment. ADEs originate from the inappropriate use of the drug and its pharmacological property, or is associated with con-founders, which occur during drug therapy but are not necessarily caused by the pharmacology of the drug itself (ACCP, 2015).

To assess the origin of an ADE, one must separate the different characteristics of a drug product and the association of ADEs with the specific attributes of the drug molecule itself and the possible contribution regarding the formulation. Reportedly, there are cases with ADEs reported after the use of modified release oral dosage forms, in particular, the ones with a delayed effect (e.g.: osmotic minipump tablets), or injections and inhalation products with different preservatives (e.g.: benzalkonium chloride or benzyl alcohol). Furthermore, when the bioavailability is compromised due to inappropriate use, as in the case of intramuscular injections, the risk of ADE is also increased due to the variability of serum concentrations. Topical formulations bear the risk of irritation and the possible ADEs originated from the systemic absorption of the active and non-active API (Uchebogu and Florence, 1996).

Since there is no specific patient safety risk assessment methodology for medications sold on the internet, a new tool was developed based upon the two quality and safety standard resolutions for pharmacy preparations in pharmaceutical practice, published by the European Directorate for the Quality of Medicines in 2016 (EDQM, 2016a, 2016b; Mackey and Nayyar, 2017; Fittler et al., 2018b; Mackey et al., 2018; Li et al., 2019).

Our aim was to develop a complex method to select products associated with a high patient safety risk regarding the online pharmaceutical market. With the inclusion of risk factors originating from the product itself, consumer perspective, and potential of counterfeiting will result in improved surveillance and test procurement studies.

Thus, an original complex risk assessment methodology has been developed based on published literature and professional expertise to provide a recommended tool for research and authority test procurement. This general tool can be used for most medication classes, however adaptation to the specific properties to the given drug group is required. In order to illustrate the real world applicability of the developed risk assessment method, various ophthalmic medications have been evaluated, and the assessment of online availability regarding high-risk products have been completed.

2.1. Research instrument

Patient safety is comprised of several definitions throughout published literature. We define patient safety risk based on the broader perspective of medication errors, since patient safety risk is a risk which may cause or lead to inappropriate medication use and patient harm based on the characteristics of the product itself or the environment (beyond the traditional drug supply chain and control of health care system) while the medication is in the control of the patient or consumer. Based on these definitions, we assumed inappropriate medication use can lead to patient harm by increasing the likelihood of Adverse Drug Events (ADEs) (Hughes, 2008; WHO, 2020; FIP, 2020).

ADE is defined by the WHO as any untoward occurrence which may present itself during treatment associated with a pharmaceutical product which does not necessarily have a causal relationship to treatment. ADEs originate from the inappropriate use of the drug and its pharmacological property, or is associated with con-founders, which occur during drug therapy but are not necessarily caused by the pharmacology of the drug itself (ACCP, 2015).

To assess the origin of an ADE, one must separate the different characteristics of a drug product and the association of ADEs with the specific attributes of the drug molecule itself and the possible contribution regarding the formulation. Reportedly, there are cases with ADEs reported after the use of modified release oral dosage forms, in particular, the ones with a delayed effect (e.g.: osmotic minipump tablets), or injections and inhalation products with different preservatives (e.g.: benzalkonium chloride or benzyl alcohol). Furthermore, when the bioavailability is compromised due to inappropriate use, as in the case of intramuscular injections, the risk of ADE is also increased due to the variability of serum concentrations. Topical formulations bear the risk of irritation and the possible ADEs originated from the systemic absorption of the active and non-active API (Uchebogu and Florence, 1996).

Since there is no specific patient safety risk assessment methodology for medications sold on the internet, a new tool was developed based upon the two quality and safety standard resolutions for pharmacy preparations in pharmaceutical practice, published by the European Directorate for the Quality of Medicines in 2016 (EDQM, 2016a, 2016b). The idea was to incorporate the product related risks such as microbiological contamination, dosage form, pharmacological effect, therapeutic window and safety profile of the preparation of parenteral and other compounded dosage forms into a checklist that can help to identify which patient safety risks are relevant in case of the internet purchase of a drug product. The tool includes patient safety risks originated from the product itself (intrinsic risks), the potential for internet purchase (extrinsic risks) and the risks of counterfeiting based on the current WHO definition (WHO, 2017). The extrinsic risks were identified based on the authors previous experiences with test purchases and pharmacist expertise (Vida et al., 2017; Fittler et al., 2018a, 2018b).

Based on published literature, the two main potential motives for consumers when considering procuring pharmaceuticals using the internet market are low cost and the unavailability of medication in the legal supply chain (Mackey and Liang, 2012; Ashames et al., 2019; Bowman et al., 2019). In inexplicably, anonymity of the internet is perceived as a benefit as consumers may turn to illegal internet pharmacies aiming to procure purchase substances intended for recreational use, or abuse (Jena et al., 2011; Corazza et al., 2014; Kalyanam et al., 2017).

Beside the severity of patient safety risks, the probability of online procurement is also a part of the tool. In consideration of the evaluation of the online market and the probability of the patient safety risk, a partial (second type of research mentioned in the introduction) test purchase method was used. In order to simulate the consumers, we used a Google engine with the search terms “buy” and “API International Nonproprietary Names (INN) name” in English. The first fifty search engine results were examined in May 2018, and sites offering eye drops with the defined API directly to patients (internet pharmacies) were included in our study. The number of relevant search results and product costs were documented. During our search, the authors were not signed into any account and the browser was set to standard security settings. Social media sites, blogs and forums were also included.

2.2. Data

Product specific information were extracted from the Summary of Product Characteristics (SmPC) and Patient Information Leaflet (PIL). As previous studies showed, medicines and other health products purchased over the internet typically arrive without a PIL or misleading labelling. Without detailed and appropriate counseling, the proper use of ocular dosage forms cannot be effectively guaranteed, increasing the risk of adverse drug events. Furthermore, if and when there is no product information on the website or disclosed product information, the consumer may not be cognizant of the recommended storage likely compromising product quality and safety. However, it is also not known whether the product was stored and handled properly during the transportation or before it. The transportation, storage temperature and circumstances (humidity, light, mechanical shock) can affect the physical, chemical and microbiological stability of the product. The latter characteristics are affected by the preservative content and whether the product is single-dose or multi-dose (Lagan et al., 2014; Mackey and Nayyar, 2016; Piñero-López et al., 2016; Tesgaw et al., 2017; Vida et al., 2017; Agarkhed et al., 2018; Sengupta et al., 2018).

2.3. Analysis

In order to demonstrate the applicability of our method we have selected a therapeutic drug category that we thought to have higher patient safety risk when purchased outside the closed drug supply chain. Their compromised quality, inappropriate use or misuse may lead to local or systemic health consequences (Kadri...
Ten commonly used eye drops available in community pharmacies throughout Hungary were selected as model products to illustrate the tool. Various medications, including prescription-only and over-the-counter products and eye drops with supply disruptions were included in our study sample. The characteristics of the selected products were also diverse, including eye drops used in the treatment of glaucoma, allergy, infection, or used for diagnostic procedures (mydriasis). The selected products are highlighted in Table 1.

2.4. Validity

The content validity of our tool was checked by the four authors, as the dimensions, sub-dimensions and the scoring system were tested separately by each author and the final scoring system based on a consensus. The applicability of the tool was tested with the 10 eye drops (see in Supplement 2).

3. Results

3.1. The dimensions of patient safety risk assessment of medicinal products

The proposed dimensions of the framework are suitable for all drug classes, however to improve the specificity of the risk assessment, customized sub-dimensions are required in accordance with the evaluated therapeutic categories or selected dosage forms. In nearly each dimension and sub dimension (except the complexity of application, where we used a 3 point scale) of the patient safety risk assessment, we selected Yes or No questions equaling 1 and 0 points in the scoring system. The total point for each patient safety risk dimension is based upon the number of sub dimensions (see Table 2 and Supplement 2).

1. General pharmaceutical risk

The general pharmaceutical risk dimension describes the ADE risk originated from the dosage form, administration route and application or administration techniques of the medical products. These risks are augmented when medications are procured and used without supervision of a health care specialist (ASHP, 1993; Dedefo et al., 2016).

The Institute for Safe Medication Practices (ISMP) maintains a list of high-alert medications in acute care setting, and medications liable to cause significant patient harm if not used properly. These mainly include parenteral and narrow therapeutic index (NTI) drugs (ISMP, 2018). Although eye drops are not on the previously mentioned list, the topical application of ocular drugs may cause adverse ocular or systemic side effects. It should be noted that not just the improper application, but the proper use of eye drops may cause systemic absorption. Systemic absorption can be a result of the high concentration of API and the different absorption mechanism through the cornea, conjunctiva and nasal mucosa (Blix et al., 2010; Farkouh et al., 2016).

Table 1

| Product brand name (Hungarian) | Active pharmaceutical ingredient |
|-------------------------------|----------------------------------|
| BETOPTIC 5 mg/ml (eye drop)   | Betaxolol                        |
| AZOPT 10 mg/ml (suspension eye drop) | Brinzolamide                      |
| CILOXAN 3 mg/ml (eye and ear drop) | Ciprofloxacin                     |
| ALLEOPTI 20 mg/ml (eye drop) | Sodium cromoglicate              |
| HUMAPENT 5 mg/ml (eye drop) | Cyclopentolate                    |
| SPERSALLERG 0.5 mg/ml + 0.4 mg/ml (eye drop) | Antazoline & tetryzoline         |
| VISINE CLASSIC 0.5 mg/ml (eye drop) | Tetryzoline                      |
| COSOPT UNO 20 mg/ml + 5 mg/ml (single dose eye drop) | Dorzolamide & timolol             |
| XALACOM 0.05 mg/ml + 5 mg/ml (eye drop) | Latanoprost & timolol             |
| TRAVATAN 40 μg/ml (eye drop) | Travoprost                       |

Table 2

| Dimensions of risk assessment | Sub-dimensions focusing on the risk factors specific to the evaluated drug class |
|-------------------------------|---------------------------------------------------------------------------------|
| INTRINSIC RISKS | 1. General pharmaceutical risk |
| 1.1. Dosage form | 1.2. Complexity of application |
| 2. Therapeutic risk | 2.1. Mode of action |
| 2.2. Systemic absorption | 2.3. Altered absorption (Indication including damaged eye) |
| 2.4. Narrow therapeutic index (NTI) | 2.5. Special patient group (Pediatric indication) |
| 3. Risk of microbiological contamination | 3.1. Single-dose vs. Multi-dose or Antimicrobial filter |
| 3.2. Preservative content | 3.3. API is an antibiotic |
| EXTRINSIC RISKS | 4. Augmented demand for online purchase |
| 4.1 Limited access (drug shortage, prescription requirement) | 4.2. Misuse potential (off-label indications, illegal use) |
| RISK OF COUNTERFEITING | 5. Unregistered/ unlicensed: Medical products which have not undergone evaluation and/or approval by the National or Regional Regulatory Authority (NRA) for the market in which they are marketed/distributed or used, subject to permitted conditions under national or regional regulation and legislation |
| 5.1. Based on preliminary evaluation whether the drug product is unregistered, investigational, or withdrawn. | Determined only by physical examination or by the verification of the serialized product. |
| 3.3. API is an antibiotic | Only complete analytics can assess safety risk. |

1 Risk of falsification and substandard quality cannot be integrated in the pre-purchase assessment, as such properties are undeterminable without physical and analytical examination. Accordingly, complete counterfeit risk assessment can be performed following actual purchase and delivery of products.
Patients afflicted with tissue injuries, compromised metabolic capacity or immature blood–brain barrier function (e.g.: children or elderly) may experience systemic side effects after the application of topical formulas. In this section the medicinal product earns 1 point if it is a parenteral (e.g.: injection or topical) or modified release dosage form and 0 point if it is a conventional oral dosage form (Batchelor and Marriott, 2015).

The complexity of application was assessed on a three point scale based on the number of instructions for appropriate application in the SmPC and PIL. In case of the evaluated ophthalmic medications, the following categories were determined: >10 instructions – 3 points, 5–10 instructions – 2 points, <5 instructions – 1 point. Comprehensively, a product can be allocated a maximum 4 points regarding this dimension.

2. Therapeutic risk

Therapeutic risk dimension describes the ADE risk originated from the pharmacological property of the API. It consist of the assessment of the therapeutic window, indication in special patient groups. Drugs with narrow therapeutic index (NTI) are drugs with small differences between therapeutic and toxic doses. These products are more likely to cause ADEs than non-NTI-drugs (Iyer et al., 2018).

Further risk factor analysis showed in addition to the patient’s age and gender, health service-related (barrier to service), genetic factors (e.g.: CYP enzymes), disease related (e.g.: infectious diseases) and medication related factors, such as the inappropriate use of the medication or intravenous drug administration are more likely manifest in ADEs. Special patient groups such as the elderly, pregnant women and pediatric patients are also more likely to develop ADEs than non-NTI-drugs (Iyer et al., 2018).

To measure the therapeutic risk, we identified five main characteristics based on the SmPC reflecting the biopharmaceutical and pharmacological properties of the API and the preparation (Raynor et al., 2014). Ophthalmic preparations can be applied to have a local effects on the surface of the eye, as in case of artificial tears, or to reach systemic effect in the eye (e.g.: drugs to treat glaucoma). Although, the aim of the treatment is the eye itself, there is ample evidence when locally applied ophthalmic preparations had unwanted systemic effects. For example, vasoconstrictor eye drops can elevate blood pressure (cyclopentolate) or beta-blockers may cause bradycardia and bronchoconstriction (timolol) (Farkouh et al., 2016; Vaajanen and Vapaatalo, 2017). Since these products have relatively poor penetration, the products may contain high concentration of an active pharmaceutical ingredient (Labetoulle et al., 2005; Farkouh et al., 2016).

Specifically, information regarding (1) mode of action can be retrieved from the SmPC. When the product is intended for local effects, there is a lower chance for systemic absorption and adverse drug event (0 points), compared with, when there is a case of systemic ophthalmic effect, that has a higher risk of systemic absorption and occurrence of adverse drug event, therefore the product reaches 1 point. When the SmPC contains data or a warning regarding the systemic side effect or adverse drug reaction based on (2) systematic absorption, similarly to the previous criteria, the product gets 1 point, if there is no systemic ADRs, the point allocated is 0 point (Davies, 2000; Labetoulle et al., 2005; Farkouh et al., 2016; Vaajanen and Vapaatalo, 2017).

We used the SmPC to identify possible local adverse drug reactions including criteria based on the frequency categories recommended by the Council for International Organizations of Medical Sciences (CIOMS): very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1000 to <1/100); rare (≥1/10,000 to <1/1000); very rare (<1/10,000); Frequency not known (cannot be estimated from the available data) (Neubert et al., 2013; Sterling and Irwin, 2015; Agrahari et al., 2016) and the severity (minor, moderate, severe). In the case of at least one very common, or common or severe local ADR, the product gets 1 point (Petrova et al., 2017). When there is an inflammation in the eye, the penetration can also be heightened via the increased blood flow and lymphatic channels (Hornof et al., 2005; Farkouh et al., 2016). If the product is used to treat damaged or on a recently operated eye, the risk of systemic absorption and adverse drug reaction was high (1 point). If the (3) indications included inflammatory ophthalmic disorders there is also a greater chance of systemic absorption and adverse drug reaction (1 point) (Sterling and Irwin, 2015; Agrahari et al., 2016). In this section we also assess whether the products contain (4) NTI active pharmaceutical ingredient (1 point in the case of Yes). From the European Directorate for the Quality of Medicines resolution aiming the pharmacy preparation, we used the criteria “type of preparation” and considered the product more likely to cause systemic adverse drug reaction if the product had (5) pediatric indication (<6 years old) in the SmPC (1 point) (EDQM, 2016a; Farkouh et al., 2016). Comprehensively, a product can achieve a maximum 5 points (5 Yes or No questions) in this dimension.

3. Risk originated from the likelihood of microbiological contamination

Microbiological safety is one of the greatest concerns of the two EDQM resolutions. Therefore, we included a combined microbiological contamination risk originating from both the dosage form, the technology of the medication and the API’s pharmacological property (Kaushik et al., 2011; Teuchner et al., 2015; Tsegaw et al., 2017).

In case of counterfeit and illegally procured medications, serious patient safety risks may arise from the microbiological contaminations. This is a significant public health risk regarding individual infections and the global spread of microorganisms from developing countries to developed ones and vice versa which originates from the poor hygienic conditions during manufacturing, distribution, especially in case of sterile dosage forms (e.g.: eye drops and evidently parenteral medications). Studies show in the case of falsified and internet purchased medicines, there is a greater risk of microbiological contamination, and not just for tablets and capsules, but also for parenteral dosage forms (Mugoyela and Mwambete, 2010; Kaushik et al., 2011; Pullirsch et al., 2014; Teuchner et al., 2015). A retrospective study performed in Shanghai, China, investigated patients undergoing intraocular injection in 2010 and found endotoxin as the cause of intraocular inflammation following the injection of a counterfeit bevacizumab (Wang et al., 2013).

Additionally, microbiological contamination is of major concern during the preparation and use of ophthalmic preparations, as it may lead to bacterial and fungal ophthalmic infections. Notably, it is not merely the microbiological stability that plays an important role and should be assessed, but the chemical and physical characteristics which are susceptible to environmental changes, the different formulations (e.g. single-dose, multi-dose) or the preservative content (e.g. preservative free) of the product also should be taken into consideration, especially when the only difference between two eye drops is the single-dose or multi-dose form (Brudieu et al., 1999; Nentwich et al., 2007; Tsegaw et al., 2017).

Further evaluated parameters in this dimension include an active pharmaceutical ingredient with antibiotic effect or the use of a special antimicrobial filter (Baudouin et al., 2010; Saisyo et al., 2016, 2017; Kyei et al., 2019).

When a product is single-dose, the risk of microbiological contamination is low, accordingly the product is allocated 0 point, while in case of multi-dose products it is 1 point. If the product...
has a special antimicrobial filter, the risk of contamination is low (0 point), and if there is no filter, the product gets 1 point. Similarly, if it contains a preservative, it is 0 point, and if there is none, the products is 1 point. When the active pharmaceutical ingredient is an antibiotic, the risk of microbiological contamination is lower (0 point), and when it is not, it is more likely to happen (1 point). Consequently, products can acquire a maximum 3 points in this dimension, as the authors think that the 3 methods to prevent microbiological contaminations (3.1. Single-dose vs. Multi-dose or Antimicrobial filter; 3.2. Preservative content; 3.3. API is an antibiotic) are equally effective and therefore no differences can be made in score system.

4. Risk originated from the limited access to the product

To assess the risk of an internet procurement of a medication, we must first know whether there is an increased demand for the active ingredient or product beyond the traditional supply chain. In case of prescription-only medications (or products only available in hospital care), products with several off-label or illegitimate indications, drugs in shortage, patients/consumers or even health professionals may turn to the internet market to overcome such restrictive barriers (Liang and Mackey, 2012a, 2012b).

For the assessment of limited access and drug shortages, we developed a complex method where we evaluate whether if it is an official shortage or it affects essential medicines and how it can be solved such as with generic substitution, compounding or other alternative therapy. We also considered the consequences of a shortage, for example when the alternative therapy is less safe or there is an increased risk of Medication errors (MEs) due to change of the originally prescribed or ordered product (Liang and Mackey, 2012b; EAHP, 2018; Fox and McLaughlin, 2018; Roth et al., 2018). However the complex evaluation is not in balance with the weight in this patient safety risk assessment. To exclude the dominance of this element, we simplified the points that can be earned in this section (1 point if it was in shortage in the evaluated period, and 0 point if not).

As it was previously mentioned, once a product has several indications, potential off-label or illegal uses, there is a greater chance it will be available on the Internet. To identify off-label use, we evaluated the authorized list from the Hungarian National Institute of Pharmacy and Nutrition. The addiction and abuse potential was assessed based on the information presented in the SmPC, while a literature search was used to determine if the API of the product is used illegally. In this category, the product is allocated 0 or 1 point (Mitchell and Dunnavan, 1998; St George et al., 2004; László, 2007; Mackey and Nayyar, 2016; Aronson and Ferner, 2017; Vida et al., 2017; Interpol, 2020; NPIP, 2020a).

5. The risk of counterfeiting

The risk of counterfeit medicine dimension is based on the interpretation of WHO 2017 counterfeit medicine definition. The definition differentiate between three main categories including unregistered/unlicensed medicines, falsified medicines and substandard medicines in the broader definition of counterfeit pharmaceuticals. From these we selected the unregistered/unlicensed medicines to be include in the risk assessment, since it can be evaluated without the actual procurement of the product. With preliminary evaluation using the national drug authority databases (NPIP in Hungary), the researcher can determine whether the product offered online is an investigational drug product, a product not registered in the defined country (in our case, Hungary), or if it was withdrawn from the market (NPIP, 2020b).

If a drug product is identified as potentially counterfeit, the patient safety score is automatically 15 points and reaches the highest patient safety risk. The falsified and substandard dimensions were excluded from our risk assessment, since they can only be determined following procurement and receipt of the product, with physical examination or electronic verification (Falsified Medicine Directive or Drug Supply Chain Security Act), accompanied by a complete quality test with analytics and microbiological testing (US House of Representatives, Committee on Energy and Commerce, 2014; Smith et al., 2014).

The detailed score system of the comprehensive patient safety risk assessment specific to eye drops and the result of the estimation of consequence/severity is shown in Supplement 2.

3.2. The measure of patient safety risk for the selected eye drops

The general pharmaceutical risk score varied between 2 and 4 out of maximum 4 points in case of the selected products. Ciprofloxacin eye drop according to the SmPC posed a risk of systemic absorption as the indications included damaged or operated eye (treating inflammatory eye diseases and corneal ulcer). The risk originated from the complexity of application was allocated the highest with 3 points in case of dorzolamide & timolol (S01ED51) eye drops as their SmPC contained more than 10 instructions.

In case of betaxolol (S01ED02), ciprofloxacin (S03AA07), latanoprost & timolol (S01ED51), and dorzolamide & timolol (S01ED51) the eye drops got the maximum 1 point, as the supervised use of these products can also cause systemic ADRs. It should be noted that three products contain beta 2-adrenergic receptor antagonists, and as previously highlighted, local beta-2-adrenergic antagonists are proven to cause bronchoconstriction in asthma patients.

In case of risk from the likelihood of microbiological contamination, only the ciprofloxacin got 1 point out of the 3, as the active pharmaceutical ingredient is an antibiotic, therefore increasing microbiological stability. All the products were multi-dose and contained a preservative (primarily benzalkonium chloride and/ or BKC), and did not have any special antimicrobial filter. When we evaluated the products’ limited access, only the cyclopentolate (S01FA04) and dorzolamide & timolol (S01ED51) preparations were in shortage for more than two weeks throughout Hungary in May 2018. The latter combination also appeared on the WHO Essential Medicine List. Both products were allocated 1 point. We did not find any evidence regarding abuse potential nor misuse for any of the evaluated medications. When evaluating the online market during the partial test purchase method, the authors did not identify any unregistered/unlicensed medicines. Out of the maximum 15 points, the dorzolamide & timolol (S01ED51) product was allocated the highest score at 10 points, followed by cyclopentolate (S01FA04) with 9 points. The weighted patient safety risk was also calculated (the total patient safety risk score was divided by 10 points) and three distinctive categories were established with low (0.00–0.25), medium (0.26–0.74) and high (0.75–1.00) risk categories. None of the eye drops scored below 0.50. The detailed calculation of the patient safety risk scores for internet procurement of the selected eye drops can be seen in Supplement 2.

3.3. The probability of the online purchase of eye drops

Following the identification of the severity/consequence of the patient safety risks associated with the internet procurement of various medicines, the probability of product availability must also be assessed. We hypothesized that the number of vendors offering a given product online reflects its internet market share. The number of relevant links (links leading customers to websites offering medication for sale) within the first 50 Google search engine results were documented for each medication. The product availability point was calculated as a proportion compared to the high-
est number of relevant links of a given product (20) in our study, and three categories were established: high accessibility products with 15 or more links (1), medium accessibility products with number of links between 5 and 14 (0.5), and products with low accessibility with less than 5 links (0.25). Interestingly, it is not just supply, but demand also influences the online pharmaceutical market, thus the perspective of the consumers was also included in our methodology. We assumed, consumers are more likely to procure from those vendors offering their products at a lower or substantially reduced price. Consequently, we documented the total price (including shipping and handling fees) for each relevant retailer and categorized the products based on their online internet market affordability (1 = low price range; 0.5 = medium price range; 0.25 = high price range). The product was allocated 1 point if the price was less than $25, and 0.5 if the price was between $25 and $50, and 0 if it's cost was more than $50. Cost categories were determined based on 5% and 10% of the Hungarian minimal wage in 2018, and in accordance with the national copayment database. Costs charged to patients in the legal national supply chain with a reimbursement were lower than $25 in case of all the products. The total weighted probability of online procurement was calculated by multiplying the availability and affordability scores, resulting in three main categories (0.0–0.25 = low; 0.26–0.74 = medium; 0.75–1.00 = high).

The detailed calculation regarding the probability scores for internet procurement of the selected eye drops is exhibited in Table 3. The online availability of eye drops in general, is relatively low, however medications treating glaucoma containing betaxolol or brinzolamide are more commonly offered for sale, while timolol & dorzolamide products online availability was the highest amongst all eye drops included in our study. Another popular product on the internet is the cromoglicate antiallergic eye drop, with 11 links. The cost range of the evaluated eye drops are generally higher than the reimbursed community pharmacy prices throughout Hungary (on average, twofold), price categories (likelihood of procuring online) were defined, aiming to simulate national (Hungarian) customer decisions.

Based on our complex risk assessment method, dorzolamide & timolol (501ED51) eye drops were selected for test purchase with reaching the highest score in both categories, which is 10 points in the patient safety risk assessment and the highest probability score with 1 point. Three samples of timolol & dorzolamide eye drops were test purchased by the Authors in 2018 for detailed chemical and microbiological analysis. Fig. 1 illustrates the final risk assessment matrix consist of the patient safety risk score and the internet purchase probability score of the selected eye drops.

### 4. Discussion and conclusion

As it was mentioned in the introduction, 58.1% of the test purchases included some kind of preliminary selection parameters or criteria such as sales data or API with high ADR potential (EAASM, 2008; Gelatti et al., 2013). Primarily researchers focused on products or APIs being popular in that days, systemic or fully explained motivations or methods were not discussed. Consequently there were many variables and the results originated from these studies were hard to compare without the same inclusion methods. Also four years ago our research group used the sales data and some motivations, but not in a standardized form. During the years we have had the motivation to develop a complex methodology called the risk based safety mapping of online pharmaceutical market, that was first introduced in 2017 in the International Journal of Clinical Pharmacy (Vida et al., 2017). In this article, we assumed there is a higher demand for somatropin products as being prescription-only medications and owning several unauthorized...
indications (e.g.: anti-aging) (Olshansky and Perls, 2008). The exact products were selected based on their national sales data. During the years we have not encountered any comprehensive method for preliminary risk assessment of medicines in the online pharmaceutical market. That is why we aimed to develop a complex and generally usable tool to measure patient safety risks and probability of the online medication purchase to select products for test purchases.

The main advantage of this newly developed method that it is a general framework with objective criteria regarding the pharmacological, technological, biopharmaceutical profile of the medication and the characteristics of the online internet market, so it can be used for other dosage forms and therapeutic categories as well. The authors think that the incorporation of the pharmacist perspective and that the tool can help to quantify patient safety risks in a rapid and objective way using readily available information sources is a great added value to the literature. However, the proposed framework is suitable for all drug classes, specific tailor-made modifications are required based on the type of research. Consequently, it is also cost-effective, since test procurement cannot be completed for all pharmaceuticals in the online pharmacy market. With an available low cost method the number of test purchases can multiply, accordingly this method may increase the overall safety of the online pharmaceutical market.

The methodology incorporates and emphasizes consumer perspective into the test procurement method when evaluating online pharmaceutical market. Furthermore, this complex methodology combines the characteristics of the products and the internet market. Hence, it can also be used in the legal internet sale of pharmaceuticals to identify products that should be counseled more thoroughly or medical follow up should be added when sold online by authorized pharmacies and pharmacists.

Additionally pharmacy owners or pharmacists responsible for this service of a community pharmacy can use this tool before starting an online pharmacy and screen the potential product portfolio (medicines and dietary supplements) to select products that can be sold safely via the internet. Besides the pharmacies, the pharmaceutical authorities will be able to use our tool to inspect the operation and patient safety of online vendors offering health care products. Also it can contribute to the pre-purchase vendor analysis and counsel.

Fig. 1. Risk assessment matrix for the selected eye drops.

The evaluation of the online pharmaceutical market has been in the focus of pharmacists and authorities in the last 20 years, which resulted in many regulations (e.g.: Falsified Medicine Directive and common EU logo), however their efficacy is debatable. That is why more and more unique techniques and methodologies are used to fight the illegal online vendors and protect patients and consumers. Beside these novel anti-counterfeiting approaches (“big data”, “infoveillance”, web crawling and deep learning models with artificial neural networks), further improvement of the traditional methods can also help the different actors in the combat against illicit online pharmacies. We think that our tool is applicable to prepare test purchase studies for academics and for authorities as well. Also the efficacy of joint health policy and forensic interventions (e.g.: PANGEA) can improve with a preliminary patient safety risk assessment.

Our future research directions include the publication of the quality and microbiological analysis of the ordered dorzolamide & timolol combination eye drops. Also we would like to continue the test purchases and the complex risk based safety mapping of online pharmaceutical market (see in the International Journal of Clinical Pharmacy Vida et al., 2017) and maybe expand and tailor our tool to the dietary supplement counterfeiting as well. Additionally we try to use this tool to the preliminary analysis and data source for the advanced computational methods (specified web crawlers) to detect and mitigate cybercriminal activity. We believe that in order to effectively prevent patient safety risks associated with the uncontrolled purchase of medication online, risk assessment based targeted interventions are required that can focus on products and active pharmaceutical ingredients with increased patient safety risks and active presence on the internet market.

**Declaration of Competing Interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

**Acknowledgements**

The authors wish to express their special gratitude to Professor Dr. Tamás Paál for the excellent review, his beneficial comments supporting the draft version of our work and lastly, his guiding advice and counsel.

**Funding**

The project was supported by the University of Pécs, Medical School grant (KA-2019-17) and European Union, co-financed by the European Social Fund (EFOP-3.6.1.-16-2016-00004).
Mackey, T.K., Nayyar, G., 2017. A review of existing and emerging digital technologies to combat the global trade in fake medicines. Expert Opin. Drug Saf. 16 (5), 587–602. https://doi.org/10.1080/14740338.2017.1313227.

Mackey, T.K., Kalyanan, J., Klugman, J., Kuzmenko, E., Gupta, R., 2018. Solution to detect, classify, and report illicit online marketing and sales of controlled substances via Twitter: Using Machine learning and web forensics to combat digital opioid access. J. Med. Internet Res. 20 (4), e10029. https://doi.org/10.2196/10029.

Memmel, L.M., Miller, L., Gardner, J., 2006. Over-the-internet availability of hormonal contraceptives regardless of risk factors. Contraception 73 (4), 372–375. https://doi.org/10.1016/j.contraception.2005.10.001.

Mitchell, G.A., Dunnavan, G., 1998. Illegal use of beta-adrenergic agonists in the United States. J. Anim. Sci. 76 (1), 208–211. https://doi.org/10.2527/1998.761208X.

Moraes, D.R., Dreischulte, T., Lipworth, B.J., Donnan, P.T., Jackson, C., Guthrie, B., 2016. Respiratory effect of beta-blocker eye drops in asthma: population-based study and meta-analysis of clinical trials. Br. J. Clin. Pharmacol. 82 (3), 814–822. https://doi.org/10.1111/bcp.13006.

Mugoya, V., Mwambete, K.D., 2010. Microbial contamination of nonsterile pharmaceuticals in public hospital settings. Ther. Clin. Risk Manag. 6, 443–448. https://doi.org/10.2147/TCM.S12253.

National Institute of Pharmacy and Nutrition (NIPN), 2020a. Official authorized off-label licenses from the National Institute of Pharmacy and Nutrition Hungary. https://www.ogyei.gov.hu/egyhembp/yukvantartasok_listak (accessed 27.06.2020).

National Institute of Pharmacy and Nutrition (NIPN), 2020b. Drug product database. https://ogyei.gov.hu/main_page (accessed 27.06.2020).

Nayyar, G.M.L., Breman, J.G., Herrington, J.E., 2015. The global pandemic of falsified medicines: laboratory and field innovations and policy perspectives. Am. J. Trop. Med. Hyg. 92 (6 Suppl), 2–7. https://doi.org/10.4269/ajtmh.15-0212.

Nayyar, G.M.L., Breman, J.G., Mackey, T.K., Clark, J.P., Hajju, M., Littrell, M., Herrington, J.E., 2019. Falsified and substandard drugs: Stopping the pandemic. Am. J. Trop. Med. Hyg. 100 (5), 1068–1065. https://doi.org/10.4269/ajtmh.18-0981.

Nentwich, M.M., Kollmann, K.H., Meshack, J., Ilako, D.R., Schaller, U.C., 2007. A systematic review and meta-analysis of clinical trials. Br. J. Clin. Pharmacol. 82 (3), 814–822. https://doi.org/10.1111/bcp.13006.

Norbutas, L., 2018. Offline constraints in online drug marketplaces: An exploratory study and meta-analysis of a cryptomarket trade network. J. Med. Internet Res. 13, 15, 34. https://doi.org/10.1186/s12911-019-02702-0.

Olshansky, S.J., Perls, T.T., 2008. New developments in the illegal provision of pharmaceuticals in public hospital settings. Ther. Clin. Risk Manag. 6, 443–448. https://doi.org/10.2196/10029.